HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.